當(dāng)前位置： 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
Decitabine 地西他濱
| 貨號(hào) | IEP1084 | 售價(jià)（元） | 728 |
| 規(guī)格 | 5mg | CAS號(hào) | 2353-33-5 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
|
貨號(hào) |
名稱 |
規(guī)格 |
價(jià)格 |
|
IEP1084-0005MG |
Decitabine(NSC127716, 5AZA-CdR) |
5MG |
728 |
|
IEP1084-0010MG |
Decitabine(NSC127716, 5AZA-CdR) |
10MG |
1180 |
|
IEP1084-0025MG |
Decitabine(NSC127716, 5AZA-CdR) |
25MG |
2588 |
|
IEP1084-0100MG |
Decitabine(NSC127716, 5AZA-CdR) |
100MG |
9258 |
地西他濱是一種脫氧胞苷類似物和細(xì)胞分化誘導(dǎo)劑。它能夠摻入DNA并與DNA甲基轉(zhuǎn)移酶在靶向DNA甲基化的胞嘧啶位點(diǎn)形成不可逆共價(jià)鍵，通過獨(dú)立于DNA甲基化的轉(zhuǎn)錄后機(jī)制增加γ珠蛋白的表達(dá)。地西他濱在體外重新激活表觀遺傳學(xué)沉默的腫瘤抑制基因方面顯示出顯著的功效。在結(jié)腸癌細(xì)胞系中，地西他濱可以分別增加HCT116和RKO細(xì)胞中未甲基化hMLH1和MGMT啟動(dòng)子的組蛋白H3-賴氨酸9乙酰化:甲基化比率。在T24膀胱癌細(xì)胞中，地西他濱可以增加組蛋白H3-賴氨酸9乙酰化和組蛋白H3-賴氨酸4在未甲基化的p14啟動(dòng)子的甲基化。
產(chǎn)品性質(zhì):
Cas No.：2353-33-5
別名：地西他濱; 5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716
化學(xué)名：4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
Canonical SMILES：C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
分子式：C8H12N4O4
分子量：228.08
溶解度：≥ 11.4 mg/mL in DMSO, ≥ 23.3 mg/mL in Water with gentle warming
儲(chǔ)存條件：4°C, protect from light
注意事項(xiàng):
為了您的安全和健康，請穿實(shí)驗(yàn)服并戴一次性手套操作。
References:
[1].Carlo Stresemann, Frank Lyko. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer. 2008; 123(1): 8 – 13.
[2].Jean-Pierre J. Issa, Guillermo Garcia-Manero, Francis J. Giles, Rajan Mannari, Deborah Thomas, Stefan Faderl, Emel Bayar, John Lyons, Craig S. Rosenfeld, Jorge Cortes, and Hagop M. Kantarjian. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103 (5): 1635 – 40.
[3].Hagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, Xuelin Huang, Susan O’Brien, Jorge Cortes, Stefan Faderl, Carlos Bueso-Ramos, Farhad Ravandi, Zeev Estrov, Alessandra Ferrajoli, William Wierda, Jianqin Shan, Jan Davis,
[4].Francis Giles, Hussain I. Saba, and Jean-Pierre J. Issa. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109 (1): 52 – 57.
[5].Stuart A. Scotta, Wei-Feng Donga, Calley Hirscha, David Sheridana, Stephen E. Sanchea, C. Ronald Geyera, John F. DeCoteau. 5-Aza-2-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leukemia Research. 2006; 30(1): 69 – 76.